|
Business Combinations - Additional Information (Detail) (USD $)
|
3 Months Ended | 1 Months Ended | 3 Months Ended | 3 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 29, 2012
|
Dec. 24, 2011
|
Dec. 29, 2012
Property, plant and equipment [Member]
|
Dec. 29, 2012
Land and buildings [Member]
|
Jan. 03, 2013
Subsequent Event [Member]
|
Aug. 01, 2012
Gen-Probe Incorporated [Member]
|
Dec. 29, 2012
Gen-Probe Incorporated [Member]
|
Jan. 31, 2013
Gen-Probe Incorporated [Member]
|
Oct. 31, 2012
Gen-Probe Incorporated [Member]
|
Dec. 29, 2012
Gen-Probe Incorporated [Member]
Minimum [Member]
|
Dec. 29, 2012
Gen-Probe Incorporated [Member]
Maximum [Member]
|
Dec. 29, 2012
Gen-Probe Incorporated [Member]
Developed technology [Member]
|
Dec. 29, 2012
Gen-Probe Incorporated [Member]
Customer contract [Member]
|
Dec. 29, 2012
Gen-Probe Incorporated [Member]
Trade names [Member]
|
|
| Business Acquisition [Line Items] | ||||||||||||||
| Cash paid per share | $ 82.75 | |||||||||||||
| Amount paid to shareholders | $ 3,800,000,000 | |||||||||||||
| Amount paid to equity award holders | 169,000,000 | |||||||||||||
| Net debt obtained by the Company to finance the acquisition | 3,480,000,000 | |||||||||||||
| Direct transaction costs incurred | 34,300,000 | |||||||||||||
| Remaining fair value of stock options assumed to be recognized as compensation expense | 23,200,000 | |||||||||||||
| Vesting period | 3 years 6 months | |||||||||||||
| Risk free rate | 0.50% | 0.70% | 0.41% | |||||||||||
| Expected volatility | 39.90% | |||||||||||||
| Expected life | 3 years 7 months 6 days | |||||||||||||
| Dividend, rate | 0.00% | |||||||||||||
| Weighted average fair value of stock options | $ 7.07 | |||||||||||||
| Adjustment to valuation of intangibles | 2,000,000 | |||||||||||||
| Assets held-for-sale | 2,200,000 | |||||||||||||
| Agreement to sell LIFECODES business to Immucor | 85,000,000 | |||||||||||||
| Contingent payments of up to an additional amount based on future revenue results | 10,000,000 | |||||||||||||
| Discount rate used to present value intangible assets and/or contingent consideration | 10.00% | 12.00% | ||||||||||||
| In-process research and development expense | 227,000,000 | |||||||||||||
| In-process research and development, value | 27,000,000 | 7,000,000 | ||||||||||||
| Total cost of completion of IPR&D projects | 51,000,000 | |||||||||||||
| Discount rate | 12.00% | |||||||||||||
| Finite-lived intangible assets, estimated useful life, years | 12 years 6 months | 13 years | 11 years | |||||||||||
| Fair value adjustment to increase the carrying amount | $ 107,900,000 | $ 70,600,000 | ||||||||||||